FDA Approves Lenvatinib for Differentiated Thyroid Cancer Refractory to Iodine-131

Yes

Offering a new treatment paradigm for a group of patients for whom, until recently, there has been no new effective treatment since the 1940s.

No relation
No
18/02/2015 9:12 am
There are no related objects.